Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer’s disease, says the principal investigator of research published in an early on-line version of Peptides."We found that we can develop antisense – which is a molecular compound – to cross the blood brain barrier enough to alter brain function. This can have a profound effect on treating diseases that occur because there is too much or too little of a certain kind of protein in the brain,” says William A. Banks, M.D., professor of geriatrics and pharmacological and physiological sciences at Saint Louis University and principal investigator. “The blood brain barrier is the Holy Grail – it’s the most difficult tissue to pass through."The article will run in the April print issue of Peptides.
